THRB and acute myeloid leukemia: Similarly, other established risk factors, e.g., age, disease origin (de novo vs secondary AML), and genetic markers did not significantly associate with outcome in this cohort treated within the trial (Supplemental Fig. 6) and the proportion of patients receiving allogeneic HSCT was comparable between patients with more and less diverse TRB repertoires (Table 1).